← Back to Search

Monoclonal Antibodies

LY3484356 for Breast Cancer (EMBER-2 Trial)

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, day 15
Awards & highlights

EMBER-2 Trial Summary

This trial is testing a new drug to see if it's safe and effective for treating early stage breast cancer.

Eligible Conditions
  • Breast Cancer

EMBER-2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, day 15
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, day 15 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from Baseline in ER Expression
Secondary outcome measures
Change from Baseline in Ki-67 Index
Change from Baseline in Progesterone Receptor (PR) Expression
PK: Plasma Concentration of LY3484356

EMBER-2 Trial Design

3Treatment groups
Experimental Treatment
Group I: LY3484356 Dose Level 3Experimental Treatment1 Intervention
Administered orally.
Group II: LY3484356 Dose Level 2Experimental Treatment1 Intervention
Administered orally.
Group III: LY3484356 Dose Level 1Experimental Treatment1 Intervention
Administered orally.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3484356
2021
Completed Phase 1
~190

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,618 Previous Clinical Trials
3,201,431 Total Patients Enrolled
63 Trials studying Breast Cancer
36,818 Patients Enrolled for Breast Cancer
Study DirectorEli Lilly and Company
1,347 Previous Clinical Trials
405,625 Total Patients Enrolled
20 Trials studying Breast Cancer
10,522 Patients Enrolled for Breast Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there open enrollment opportunities for this scientific experiment?

"As displayed on clinicaltrials.gov, this medical experiment is not currently enrolling participants. It was initially listed on April 21st 2021 and most recently altered on November 23rd 2022. Despite the fact that no patients are being accepted for this trial now, 2600 other studies are still recruiting volunteers."

Answered by AI

Are there various sites offering this research in the North American region?

"To date, 10 medical centres are recruiting patients for this trial. These include the University of Texas MD Anderson Cancer Center in Houston, the University of Vermont Medical Center in Burlington, and Winship Cancer Center Emory University in Atlanta; there are several other sites as well."

Answered by AI

Has the Food and Drug Administration sanctioned LY3484356 for public use?

"LY3484356 has a safety score of 1 since this is an early-phase trial, with limited evidence for its efficacy and almost no proof that it's safe."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery
2021. "A Study of LY3484356 in Women With Breast Cancer Before Having Surgery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04647487.
~21 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top